Product Data Sheet

Product Name: AXL-IN-13
Cat. No.: GC73370

Chemical Properties

Cas. No.	2376928-82-2		
Formula	$C_{34}H_{41}FN_6O_5$	M.Wt	632.72
Solubility	DMSO : 100 mg/mL (158.05 mM; Need ultrasonic)	Storage	-20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.		
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.		

Structure



Background

AXL-IN-13 is a potent and orally active AXL inhibitor (IC50: 1.6 nM, Kd: 0.26 nM). AXL-IN-13 reverses TGF-β1-induced epithelial-mesencmal transition (EMT), and inhibits cancer cell migration

and invasion.

AXL-IN-13 (compound 6li) inhibits Ba/F3-TEL-AXL cell proliferation with an IC50 of 4.7 nM (determined by ELISA)[1].AXL-IN-13 also shopws binding affinities against CSF1R, FLT1/3/4, KLT, PDGFRB, TIE2[1].AXL-IN-13 (0-500 nM, 6 h) inhibits the phosphorylation of AXL in MDA-MB-231 and 4T1 cells[1].AXL-IN-13 (0-3 μM, 3 days) blocks EMT induced by TGF-β1 (10 ng/mL) in MDA-MB-231 cells[1].AXL-IN-13 (0-3 μM, 24 h) suppresses MDA-MB-231 cell migration and invasion induced by TGF-β1 (10 ng/mL)[1].

AXL-IN-13 (compound 6li) (50 or 100 mg/kg, p.o, 14 days) inhibits 4T1 tumor growth and metastasis[1].AXL-IN-13 (25 mg/kg, p.o.) displays reasonable PK profiles with an AUC of 8410.21 ng/mL•h, a T1/2 value of 4.22 h, and an oral bioavailability (F) of 14.4%[1].

References:
[1]. Chan S, et al. Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors. J Med Chem. 2022 Nov 24;65(22):15374-15390.